MeiraGTx Narrows Q3 Loss to $51.3M as Bota-Vec Filing Nears
MGTX sits 43% above its 52-week low of $6.62.
Summary
MeiraGTx posted a Q3 2026 net loss of $51.3 million, or $0.53 per share, versus a $50.5 million loss a year earlier, with R&D spending up to $39.3 million on the AAV2-hAQP1 and bota-vec programs. Cash and equivalents stood at $186.8 million at September 30, and management says that plus a $95.0 million upfront payment due from Hologen funds operations into the second half of 2028. The operational update is the real story: the bota-vec MAA dossier is complete and slated for EMA submission in December 2026, with the FDA BLA expected in Q1 2027 ahead of a late-2027 launch. The pivotal AQUAx2 12-month data readout for radiation-induced xerostomia remains on track for mid-2027. This follows the September 8-K adding Alan Sebulsky to the board and comes after a run of routine 10b5-1 insider sales filings in August and October.
At the time of this announcement, MGTX was trading at $9.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $929.7M. The 52-week trading range was $6.62 to $15.35. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.